



# ***ANEMIA AS A PREDICTOR OF DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS***

By

**Dr. Mohammad Omar Ahmed Heiba**

*M.B., B.Ch., Faculty of Medicine – Cairo University*

*Thesis Submitted for Partial fulfillment of Master Degree  
in Internal Medicine*

**Under Supervision of**

**Prof. Dr. Abdel Azeem Mohammad Elhefny**

*Professor of Internal Medicine, Rheumatology and Immunology  
Faculty of Medicine, Ain Shams University*

**Dr. Samah Abdel Rahman Elbakry**

*Assist. Prof. of Internal Medicine, Rheumatology and Immunology  
Faculty of Medicine, Ain Shams University*

**Dr. Caroline Samy Morad**

*Lecturer of Internal Medicine, Rheumatology and Immunology  
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine- Ain Shams University*

*2016*



*I cannot give a word to fulfill my deepest love and thanks to **ALLAH** for lighting me the way not only throughout this piece of work but also throughout my whole life and for all the countless gifts I have been offered. Of these gifts, those people who were assigned to give me a precious hand so as to be able to fulfill this thesis.*

*I am greatly honored to express my deep gratitude and faithfulness to **Professor Dr. Abdel Azeem Mohammad Elhefny**, Professor of Internal Medicine, Ain Shams University. He gave me his valuable advices and support that cannot be expressed in words. His fatherhood attitude and encouragement were so supportive for the completion of this work. I would like to thank him for spending much of his precious time in fulfillment of this work. Without his meticulous guidance, unlimited support, valuable advice and wise helpful criticism, this work would never have been completed.*

*I wish to acknowledge with sincere appreciation and gratitude **Assist. Prof. Dr. Samah Abdel Rahman Elbakry**, Assistant Professor of Internal Medicine, Ain Shams University. The few words written here can never express the feelings of gratitude and kind regards I have for her supervision. Her valuable comments, efforts and collaboration were the causes to complete this work properly.*

## *Acknowledgement*

---

*I would like to express my deepest gratitude to **Dr. Caroline Samy Morad**, Lecturer of Internal Medicine, Ain Shams University, who always help me in practical work, many thanks for her meticulous supervision and sincere advice which help me on the right way.*

*My deepest appreciation for my colleagues in As-Salam International Hospital and Nasr City Health Insurance hospital  
"True friends are discovered in the times of need".*

*A special dedication to my family (my parents, my wife and my son Omar), for their never ending care. They were always supporting me and encouraging me to continue and finish this work,*



*Mohammad Omar Heiba*

## *List of contents*

<u>Subjects</u>	<u>Page No.</u>
• Acknowledgement.....	-
• List of contents . ....	-
• List of abbreviations.....	I
• List of tables .....	V
• List of figures .....	VIII
• Introduction .....	1
• Aim of the work .....	4
• Review of literature	
• Systemic lupus erythematosus.....	5
• Anemia in SLE.....	51
• Patients and methods.....	77
• Results .....	84
• Discussion .....	105
• Summary and conclusion .....	114
• Recommendations .....	116
• References .....	117
• Arabic summary .....	151



## *List of abbreviations*

<b>Abbreviation</b> <b>Abbreviation</b>	<b>Meaning</b>
<b>ACD</b>	Anemia of chronic disease
<b>ACR</b>	American College of Rheumatology
<b>AIHA</b>	Autoimmune hemolytic anemia
<b>ANA</b>	Antinuclear antibodies
<b>Anti-ds DNA</b>	Anti-double stranded deoxyribonucleic acid
<b>Anti-HLA</b>	Anti- human leukocyte antigen
<b>Anti-SSA/Ro and anti-SSB/La</b>	Anti-Sjögren's-syndrome-related antigen A and B
<b>AOSD</b>	Adult-onset Still's disease
<b>APS</b>	Anti-phospholipid syndrome
<b>BFU-E</b>	Burst forming units-erythroid
<b>BILAG</b>	British Isles Lupus Assessment Group
<b>BM</b>	Bone marrow
<b>C3, C4</b>	Complement 3,4
<b>CBC</b>	Complete blood count
<b>CFU-E</b>	Colony forming units- erythroid
<b>CNS</b>	Central nervous system
<b>CRP</b>	C-reactive protein level
<b>CSA</b>	Cyclosporine-A
<b>CT</b>	Computed tomography
<b>CYC</b>	Cyclophosphamide
<b>DHEA</b>	Dehydro-epiandrosterone
<b>DNA</b>	deoxyribonucleic acid

**List of abbreviations** (Cont.)

<b>ds-DNA</b>	Double-stranded deoxyribonucleic acid
<b>EBV</b>	Epstein-Barr virus
<b>ECLAM</b>	European Consensus Lupus Activity Measurement
<b>ELISA</b>	Enzyme-linked immunosorbent assay
<b>EPO</b>	Erythropoietin
<b>ESR</b>	Erythrocyte sedimentation rate
<b>FcR</b>	Fc receptor
<b>fL</b>	Femtoliters
<b>GCs</b>	glucocorticoids
<b>GM-CSF</b>	Granulocyte macrophage colony-stimulating factor
<b>GP</b>	Membrane glycoproteins
<b>GWAS</b>	Genome-wide association studies
<b>Hb</b>	Hemoglobin
<b>hCRH</b>	Human corticotropin releasing hormone
<b>HCT</b>	Hematocrit
<b>HGB</b>	Hemoglobin concentration
<b>HLH</b>	Hemophagocytic lymphohistiocytosis
<b>HS</b>	Highly significant
<b>IC</b>	Immune complex
<b>ICAMs</b>	Intercellular adhesion molecules
<b>IDA</b>	Iron deficiency anemia
<b>IDMS</b>	Isotope dilution mass spectrometry
<b>IFN</b>	Interferon
<b>IGF</b>	Insulin growth factor

**List of abbreviations** (Cont.)

<b>IIF</b>	Indirect immunofluorescence
<b>IL</b>	Interleukin
<b>ISN/RPS</b>	International Society of Nephrology/ Renal Pathology Society
<b>ITP</b>	Immune thrombocytopenia
<b>IVIg</b>	Intravenous immunoglobulin
<b>LAI</b>	Lupus Activity Index
<b>LDH</b>	Lactate dehydrogenase
<b>LFA</b>	Lymphocyte function-associated antigen
<b>LN</b>	Lupus nephritis
<b>MAHA</b>	Microangiopathic hemolytic anemia
<b>MAS</b>	Macrophage activation syndrome
<b>MCH</b>	Mean corpuscular hemoglobin
<b>MCHC</b>	Mean corpuscular hemoglobin concentration
<b>MCV</b>	Mean corpuscular volume
<b>MMF</b>	Mycophenolate mofetil
<b>NK</b>	Natural killer
<b>NPSLE</b>	Neuropsychiatric syndromes associated with SLE
<b>NS</b>	Non-significant
<b>pg</b>	picograms
<b>PLT</b>	Platelets
<b>PRCA</b>	Pure red cell aplasia
<b>PNH</b>	Paroxysmal nocturnal hemoglobinuria
<b>RA</b>	Rheumatoid arthritis
<b>RBC</b>	Red blood cell



***List of abbreviations*** (Cont.)

<b>RCM</b>	Red blood cell mass
<b>RDW</b>	Red cell volume distribution width
<b>RNA</b>	Ribonucleic acid
<b>S</b>	Significant
<b>SCF</b>	Stem Cell Factor
<b>±SD</b>	Mean standard deviation
<b>SLAM</b>	Systemic Lupus Activity Measure
<b>SLE</b>	Systemic Lupus Erythematosus
<b>SLEDAI</b>	Systemic Lupus Erythematosus Disease Activity Index
<b>SLICC</b>	The Systemic Lupus International Collaborating Clinics
<b>snRNPs</b>	Small nuclear ribonucleic proteins
<b>TGF-beta</b>	Transforming growth factor-beta
<b>TIBC</b>	Total iron-binding capacity
<b>TLRs</b>	Toll-like receptors
<b>TNF</b>	Tumor necrosis factor
<b>TTP</b>	Thrombotic thrombocytopenic purpura
<b>UV</b>	Ultraviolet
<b>VCAM</b>	Vascular cell adhesion molecule
<b>VWF</b>	von Willebrand factor
<b>WHO</b>	World Health Organization

## *List of Tables*

<b>Table</b>	<b>Title</b>	<b>Page</b>
1	International Society of Nephrology/ Renal Pathology Society classification of LN.	25
2	Indications for renal biopsy in patients with systemic lupus erythematosus.	26
3	Neuropsychiatric syndromes associated with SLE.	27
4	Clinical and immunologic criteria used in the SLICC.	43
5	Systemic Lupus Activity Measure (SLAM) Index.	49
6	SLICC/ACR damage index for SLE.	50
7	Normal values of red blood cell parameters.	54
8	Classic Distinguishing Features of IDA and ACD.	69
9	Description of age, disease duration, SLAM score, SLICC/ACR index and Hb concentration among patients.	84
10	Description of demographic and some lab data among group (1) anemic cases (IDA).	86
11	Description of CBC and iron profile among group (1) anemic cases (IDA).	87
12	Description of Retics, LDH and Coombs test among group (1) anemic cases (IDA).	88

**List of Tables** (Cont.)

Table	Title	Page
13	Description of SLAM activity and SLICC/ACR damage among group (1) anemic cases (IDA).	88
14	Description of demographic and some lab data among group (2) anemic cases (ACD).	89
15	Description of CBC and iron profile among group (2) anemic cases (ACD).	90
16	Description of Retics, LDH and Coombs test among group (2) anemic cases (ACD).	91
17	Description of SLAM activity and SLICC/ACR damage among group (2) anemic cases (ACD).	91
18	Description of demographic and some lab data among group (3) anemic cases (AIHA).	92
19	Description of CBC and iron profile among group (3) anemic cases (AIHA).	93
20	Description of Retics, LDH and Coombs test among group (3) anemic cases (AIHA).	94
21	Description of SLAM activity and SLICC/ACR damage among group (3) anemic cases (AIHA).	94
22	Comparison between the three study groups as regards demographic data.	95

**List of Tables** (Cont.)

Table	Title	Page
23	Comparison between the three study groups as regards ESR, C3 and C4.	95
24	Comparison between three study groups as regards 24-Hrs urinary protein and creatinine.	96
25	Comparison between three study groups as regards ANA and Anti-ds DNA.	97
26	Comparison between three study groups as regards CBC.	97
27	Comparison between three study groups as regards SLAM activity and SLICC/ACR damage scores.	98
28	Comparison between three study groups as regards Retics, LDH, Coomb's test and iron profile.	99
29	Correlation between Hb and disease activity markers.	101
30	Correlation between Hb and 24-Hrs urinary protein.	103
31	Correlation between Hb and SLICC/ACR damage score.	104

## *List of Figures*

Figure	Title	Page
1	Mechanism of autoantibody production and tissue injury in lupus.	15
2	Butterfly rash of SLE.	22
3	Erythema annulare centrifugum.	23
4	Livedo reticularis more pronounced in an upright posture.	24
5	Dependence of erythroid progenitor cells to EPO and SCF at different stages of erythropoiesis.	56
6	Showing gender distribution among patients.	84
7	Percentages of types of anemia among patients.	85
8	Comparison between three study groups as regards 24-Hrs urinary protein.	96
9	Correlation between Hb and C3.	101
10	Correlation between Hb and C4.	102
11	Correlation between Hb and SLAM activity.	102
12	Correlation between Hb and 24-Hrs urinary protein.	103
13	Correlation between Hb and SLICC/ACR damage score.	104

## *Introduction*

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder that results from a combination of genetic, hormonal and environmental factors (*Nuttall et al., 2013*). It is an unusually heterogeneous disease, characterized by autoantibody production and immune complex (IC) deposition leading to multi-organ damage (*Chung et al., 2011*).

It is a chronic, usually lifelong, potentially fatal autoimmune disease characterized by unpredictable exacerbations and remissions with protean clinical manifestations (*Hung et al., 2005*).

SLE affects the joints, skin and blood in over 80% of patients and affects the kidneys, central nervous system and cardiopulmonary system in 30%-50% of patients. Between 10% and 30% of patients have anticardiolipin antibodies that are associated with arterial and venous thrombosis. The majority of patients demonstrate systemic manifestations, which may include fatigue, malaise, fever, anorexia, nausea and weight loss (*Chang et al., 2002*).

Haematological abnormalities are common findings in SLE. Anemia is found in about 50% of patients, the most common forms of anemia in these patients are: anemia of chronic disease (ACD), iron deficiency anemia (IDA), autoimmune hemolytic anemia (AIHA), anemia of chronic renal insufficiency, and cyclophosphamide-induced myelotoxicity. It is noteworthy that ACD often coexists with anemia caused by other mechanisms. Iron deficiency is common in patients with SLE as a result of menorrhagia and increased gastrointestinal blood loss, caused by the use of non-steroidal anti-inflammatory drugs, aspirin, and oral anticoagulants (*Giannouli et al., 2006*).

Other causes of SLE associated anemia include: nutritional deficiencies (folate and B12), immune mediated, red cell aplasia, hemophagocytosis, aplastic anemia, pernicious anemia, myelofibrosis, uremia, treatment induced, hypersplenism, infection, and myelodysplasia (*Giannouli et al., 2006*).

As a chronic disease, SLE can exhibit a wax and wane course that, oftentimes, cannot be predicted or corroborated by serological tests. The predictive value that many biomarkers have in the disease course, including anti-ds-